^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    ADAM9 (ADAM Metallopeptidase Domain 9)

    i
    Other names: ADAM9, ADAM Metallopeptidase Domain 9, MCMP, MDC9, Disintegrin And Metalloproteinase Domain-Containing Protein 9, Metalloprotease/Disintegrin/Cysteine-Rich Protein 9, Cellular Disintegrin-Related Protein, Myeloma Cell Metalloproteinase, Cone Rod Dystrophy 9, Mltng, A Disintegrin And Metalloproteinase Domain 9 (Meltrin Gamma), ADAM Metallopeptidase Domain 9 (Meltrin Gamma), Meltrin-Gamma, CORD9
    27d
    Identification of proteases associated with glioblastoma and their modulation by interferon-gamma signaling. (PubMed, Eur Cytokine Netw)
    Thus, we revealed a protease profile (ADAM9, CTSB, MMP7, CTSC, CTSL, MMP9, and PLAU) associated with glioblastoma progression and further demonstrated that CTSL is regulated by IFN-γ in glioblastoma cells. These results establish a link between IFN-γ signaling and protease regulation in glioblastoma.
    Journal
    |
    IFNG (Interferon, gamma) • ADAM9 (ADAM Metallopeptidase Domain 9) • MMP2 (Matrix metallopeptidase 2) • CTSS (Cathepsin S) • MMP9 (Matrix metallopeptidase 9) • MMP7 (Matrix metallopeptidase 7) • PLAU (Plasminogen Activator)
    28d
    FOSL1 Orchestrates Epigenetic Reprogramming of Anaplastic Thyroid Cancer and Suppresses Natural Killer Cell-Mediated Antitumor Immunity. (PubMed, Cancer Res)
    Silencing FOSL1, ADAM9, or MMP9 sensitized ATC cells to NK cell-mediated cytotoxicity in vitro and suppressed ATC growth in vivo. Together, these findings highlight the role of FOSL1 in chromatin remodeling of ATC and in dampening cytotoxic functions of NK cells, thereby providing insights into the development of potential cancer therapeutics.
    Journal
    |
    ADAM9 (ADAM Metallopeptidase Domain 9) • FOSL1 (FOS Like 1) • MMP9 (Matrix metallopeptidase 9) • MMP14 (Matrix Metallopeptidase 14)
    2ms
    Integrated analysis of radiomics and RNA reveals the biological basis and therapeutic implications of aggressive hepatocellular carcinoma subtypes. (PubMed, NPJ Precis Oncol)
    KIT inhibitors may serve as potential therapeutic drugs, whereas ADAM9 and PTK2B are key genes influencing patient prognosis. The artificial intelligence model developed from MRI has emerged as a dependable method for predicting aggressive HCC, with further biological exploration offering the potential to augment its clinical utility.
    Journal
    |
    ADAM9 (ADAM Metallopeptidase Domain 9) • PTK2B (Protein Tyrosine Kinase 2 Beta)
    2ms
    Molecular and System-Level Characterization of MMP12 Suppression in Lung Cancer: A Combined Bioinformatics and Molecular Approach. (PubMed, Int J Mol Sci)
    Upstream regulator predictions implicated reduced AKT signaling alongside an ADAM9-centered adaptive axis. Collectively, these findings highlight C1, C7, C9, C10, and C15 as promising MMP12 inhibitors, supporting their further development in preclinical lung cancer and nominating the eight-gene panel as a pharmacodynamic signature for MMP12-targeted therapies.
    Journal
    |
    ADAM9 (ADAM Metallopeptidase Domain 9) • APOA1 (Apolipoprotein A-I) • NFKBIA (NFKB Inhibitor Alpha 2)
    2ms
    Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target. (PubMed, Front Immunol)
    The prognostic model EFFscore exhibits remarkable predictive performance, accurately reflecting the malignant potential of PDAC. P2RY6 serves as a key oncogenic factor driver in PDAC, its targeted inhibition significantly suppresses tumor progression, highlighting its dual potential as a diagnostic biomarker and therapeutic target.
    Journal
    |
    ADAM9 (ADAM Metallopeptidase Domain 9) • CD36 (thrombospondin receptor)
    3ms
    Liquid-liquid phase separation of ATXN2L enhances mRNA translation in hepatocellular carcinoma. (PubMed, Cell Rep)
    Moreover, the promotion of ATXN2L granules on ADAM9 translation is further enhanced via co-localization with stress granules (SGs). Together, our findings reveal that ATXN2L functions as a critical translational regulator in HCC progression through LLPS activity, which could serve as an effective therapeutic target for HCC treatment.
    Journal
    |
    ADAM9 (ADAM Metallopeptidase Domain 9)
    3ms
    Single-cell/spatial integration reveals an MES2-like glioblastoma program orchestrated by immune communication and regulatory networks. (PubMed, Front Immunol)
    MES2-like GBM is an ECM-driven, stress-adapted state with strong prognostic impact. We nominate CEBPD and TNFRSF1A/ITGB1 as actionable nodes and identify ARRDC3 as a spatially restricted effector with context-dependent tumor-modulatory functions warranting therapeutic exploration.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • TNFA (Tumor Necrosis Factor-Alpha) • ADAM9 (ADAM Metallopeptidase Domain 9) • TNFRSF1A (TNF Receptor Superfamily Member 1A) • TGFB1 (Transforming Growth Factor Beta 1) • ITGB1 (Integrin Subunit Beta 1)
    4ms
    Preclinical development of MGC028, an ADAM9-targeted, glycan-linked, exatecan-based antibody-drug conjugate for the treatment of solid cancers. (PubMed, Mol Cancer Ther)
    MGC028 exhibited specific, dose-dependent in vivo antitumor activity toward ADAM9-positive cell line-derived and patient-derived xenograft models and was well tolerated in a repeat-dose non-human primate toxicology study, with no evidence of the ocular toxicities observed with IMGC936. A first-in-human study of MGC028 in patients with advanced solid tumors has been initiated (NCT06723236).
    Preclinical • Journal
    |
    ADAM9 (ADAM Metallopeptidase Domain 9)
    |
    izeltabart tapatansine (IMGC936)
    7ms
    Molecular and Genetic Pathogenesis of Oral Cancer: A Basis for Customized Diagnosis and Treatment. (PubMed, Biology (Basel))
    The knowledge of this molecular pathogenesis has not yet been translated into clinical practice, apart from the use of cetuximab, an EGFR antibody...Liquid biopsies, either resorting to circulating tumor cells, extracellular vesicles or cell-free nucleic acids, have the potential to bypass this problem, and have potential prognostic and staging value. We critically review the current knowledge on the molecular, genetic and epigenetic alterations in oral cancer, as well as the applications and challenges of liquid biopsies in its diagnosis, follow-up, and prognostic stratification.
    Review • Journal
    |
    TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CCND1 (Cyclin D1) • CDH1 (Cadherin 1) • FAT1 (FAT atypical cadherin 1) • ADAM9 (ADAM Metallopeptidase Domain 9) • MIR21 (MicroRNA 21) • MGAM (Maltase-Glucoamylase) • SOX17 (SRY-Box Transcription Factor 17) • MIR100 (MicroRNA 100) • MIR211 (MicroRNA 211) • MIR221 (MicroRNA 221) • MIR184 (MicroRNA 184) • MIR31 (MicroRNA 31) • MIR375 (MicroRNA 375) • CTTN (Cortactin) • MIR133B (MicroRNA 133b) • MIR138 (MicroRNA 138) • MIR200 (MicroRNA 200) • MIR203A (MicroRNA 203a) • MIR222 (MicroRNA 222)
    |
    Erbitux (cetuximab)
    8ms
    Molecular Signatures of Dendritic Cell Activation upon TNF Stimulation: A Multi-Omics Study in Rheumatoid Arthritis. (PubMed, Int J Mol Sci)
    Our data reveal a TNF-responsive, pro-inflammatory transcriptional program in dendritic cells from RA patients and underscore the relevance of the TNF receptor profile in shaping DC function. These findings provide new insights into the immunobiology of RA and identify dendritic cells as potential targets for personalized immunomodulatory therapy.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • ADAM9 (ADAM Metallopeptidase Domain 9) • CCR7 (Chemokine (C-C motif) receptor 7) • CD14 (CD14 Molecule) • LAMP3 (Lysosomal Associated Membrane Protein 3) • TRAF1 (TNF Receptor Associated Factor 1)
    8ms
    Clinical Validation of ADAM9 as a Prognostic Biomarker in Oral Cancer. (PubMed, Oral Dis)
    This study identifies ADAM9 as a key driver of oral cancer in a Taiwanese cohort and highlights its diagnostic and therapeutic potential.
    Journal
    |
    ADAM9 (ADAM Metallopeptidase Domain 9) • MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9) • MMP14 (Matrix Metallopeptidase 14)